C

CSPC Pharmaceutical Group Ltd
HKEX:1093

Watchlist Manager
CSPC Pharmaceutical Group Ltd
HKEX:1093
Watchlist
Price: 7.7 HKD -0.9% Market Closed
Market Cap: 88.7B HKD

CSPC Pharmaceutical Group Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CSPC Pharmaceutical Group Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Net Income (Common)
¥4.1B
CAGR 3-Years
-11%
CAGR 5-Years
-2%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
¥4.8B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
¥2.4B
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
¥7.5B
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
¥5.2B
CAGR 3-Years
25%
CAGR 5-Years
1%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
¥3.7B
CAGR 3-Years
N/A
CAGR 5-Years
244%
CAGR 10-Years
N/A
No Stocks Found

CSPC Pharmaceutical Group Ltd
Glance View

Market Cap
88.7B HKD
Industry
Pharmaceuticals

CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.

CSPC Pharmaceutical Group Ltd Intrinsic Value
HIDDEN
Show

See Also

What is CSPC Pharmaceutical Group Ltd's Net Income (Common)?
Net Income (Common)
4.1B CNY

Based on the financial report for Sep 30, 2025, CSPC Pharmaceutical Group Ltd's Net Income (Common) amounts to 4.1B CNY.

What is CSPC Pharmaceutical Group Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
12%

Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for CSPC Pharmaceutical Group Ltd have been -11% over the past three years , -2% over the past five years , and 12% over the past ten years .

Back to Top